(CLSD) Clearside Biomedical - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1850631045
CLSD: Eye, Injection, Suspension, Treatment, Uveitis, AMD
Clearside Biomedical, Inc. (NASDAQ:CLSD) is a biopharmaceutical company pioneering the delivery of therapies to the back of the eye via the suprachoroidal space, a novel approach designed to enhance drug distribution and efficacy for ocular diseases. The companys lead product, XIPERE (triamcinolone acetonide suprachoroidal injectable suspension), is approved for the treatment of macular edema associated with uveitis, a condition causing inflammation and vision impairment. Additionally, Clearside is advancing CLS-AX (axitinib injectable suspension) through a Phase IIb clinical trial for the treatment of wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The company has established strategic collaborations with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences to expand its pipeline and capabilities. Incorporated in 2011 and headquartered in Alpharetta, Georgia, Clearside Biomedical focuses on addressing significant unmet needs in ophthalmology.
As of the latest data, Clearside Biomedical, Inc. (NASDAQ:CLSD) has a market capitalization of $78.12 million, with a price-to-book (P/B) ratio of 3.93 and a price-to-sales (P/S) ratio of 10.14. The companys return on equity (RoE) stands at 91.63%. On the technical side, the stock is trading at $0.85, below its 20-day simple moving average (SMA) of $0.98 and 50-day SMA of $0.95, while its 200-day SMA is at $1.11. The average true range (ATR) is 0.06, indicating relatively low volatility. The stocks average 20-day volume is 266,788 shares.
3-Month Forecast: Based on
Additional Sources for CLSD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLSD Stock Overview
Market Cap in USD | 65m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2016-06-02 |
CLSD Stock Ratings
Growth 5y | -58.5% |
Fundamental | -4.39% |
Dividend | 0.0% |
Rel. Strength Industry | -49 |
Analysts | 4.57/5 |
Fair Price Momentum | 0.67 USD |
Fair Price DCF | - |
CLSD Dividends
No Dividends PaidCLSD Growth Ratios
Growth Correlation 3m | -32.8% |
Growth Correlation 12m | -81.5% |
Growth Correlation 5y | -75.7% |
CAGR 5y | -9.66% |
CAGR/Max DD 5y | -0.11 |
Sharpe Ratio 12m | -2.68 |
Alpha | -60.74 |
Beta | 1.23 |
Volatility | 82.84% |
Current Volume | 75.4k |
Average Volume 20d | 204.5k |
As of March 15, 2025, the stock is trading at USD 0.89 with a total of 75,448 shares traded.
Over the past week, the price has changed by -4.11%, over one month by -16.85%, over three months by -11.91% and over the past year by -48.57%.
Neither. Based on ValueRay Fundamental Analyses, Clearside Biomedical is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -4.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLSD as of March 2025 is 0.67. This means that CLSD is currently overvalued and has a potential downside of -24.72%.
Clearside Biomedical has received a consensus analysts rating of 4.57. Therefor, it is recommend to buy CLSD.
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CLSD Clearside Biomedical will be worth about 0.8 in March 2026. The stock is currently trading at 0.89. This means that the stock has a potential downside of -13.48%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6 | 574.2% |
Analysts Target Price | 6 | 574.2% |
ValueRay Target Price | 0.8 | -13.5% |